Background and Objectives: Sugammadex is widely used in anesthesia to reverse rocuronium-induced neuromuscular blockade (NMB). In patients with compromised kidney function, most drugs show alteration of their pharmacokinetic profile with reduced clearance. The purpose of this article is to examine the efficacy, pharmacokinetics, and safety of sugammadex in end-stage renal disease (ESRD) patients receiving general anesthesia, using a systematic review. Materials and Methods: The databases of PubMed, EMBASE, the Cochrane Library, Web of Science, Scopus, KoreaMed, and ClinicalTrials.gov were searched for studies comparing the efficacy or safety outcomes of sugammadex administration for the reversal of rocuronium-induced NMB, in ESRD patients (...
Background. Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromuscul...
Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of s...
Background: The impact of sugammadex in patients with end-stage renal disease undergoing kidney tran...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
BACKGROUND: Sugammadex, a modified gamma-cyclodextrin, is the first selective relaxant binding agent...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Rocuronium is a non-depolarizing aminosteroidal neuromuscular blocking agent that is widely used in ...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Introduction: Inadequate neuromuscular blockade contributes to postoperative respiratory complicatio...
BACKGROUND: Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromuscul...
Contains fulltext : 89451.pdf (publisher's version ) (Closed access)BACKGROUND: Su...
BACKGROUND: Reversal of rocuronium-induced neuromuscular blockade can be accomplished by chemical en...
Background and objective Sugammadex has been introduced for reversal of rocuronium (or vecuronium)–i...
Background. Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromuscul...
Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of s...
Background: The impact of sugammadex in patients with end-stage renal disease undergoing kidney tran...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
BACKGROUND: Sugammadex, a modified gamma-cyclodextrin, is the first selective relaxant binding agent...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Rocuronium is a non-depolarizing aminosteroidal neuromuscular blocking agent that is widely used in ...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Background: Sugammadex reverses the neuromuscular blocking effects of rocuronium by chemical encapsu...
Introduction: Inadequate neuromuscular blockade contributes to postoperative respiratory complicatio...
BACKGROUND: Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromuscul...
Contains fulltext : 89451.pdf (publisher's version ) (Closed access)BACKGROUND: Su...
BACKGROUND: Reversal of rocuronium-induced neuromuscular blockade can be accomplished by chemical en...
Background and objective Sugammadex has been introduced for reversal of rocuronium (or vecuronium)–i...
Background. Sugammadex is a selective relaxant binding agent designed to encapsulate the neuromuscul...
Background: Rapid and complete reversal of neuromuscular blockade (NMB) is desirable at the end of s...
Background: The impact of sugammadex in patients with end-stage renal disease undergoing kidney tran...